Transatlantic Group to Discuss European View of Plant-Made Pharmaceuticals

Share Article

International Academy of Life Sciences to present at cPMP 2005.

Members of the International Academy of Life Sciences will discuss the risks and opportunities the plant-made pharmaceuticals industry faces in Europe during an upcoming conference.

The conference, cPMP 2005, to be held Jan. 30-Feb. 2 in Montreal, will bring together some 40 PMP companies (30 presenting) and hundreds of participants for a three-day session (four if you count the opening cocktail) that will look at plant-factories from perspectives including business, drug development, regulatory, science and public-perception.

Among the participants in a panel discussion on stakeholders related to PMPs will be Dr. Hilmar Stolte, IALS president and a professor at Hannover Medical School in Germany.

“While the science of PMPs is quite advanced in Europe, the application of research and development of products is much more advanced in North America. However, our experience is that the potential is there for the European public to receive this technology positively,” Stolte said.

The International Academy of Life Sciences hosts the online community, which is dedicated to a scientifically based, medically oriented discussion on plant-made pharmaceuticals. IALS is a global network of universities, medical schools, and related institutions that are dedicated to education, training and research in key issues associated with the life sciences.

On hand at the cPMP conference will be leading corporations including Amgen, Baxter Bioscience, Centocor, Novartis and Wyeth BioPharma. Companies presenting their protein-production platform, products or enabling technologies include Grand Hosts Bayer CropScience (Germany), Dow AgroSciences (USA), Nexgen (Korea), and Syngenta (Switzerland), along with Hosts that include Chlorogen, Fraunhofer, SemBioSys, Medicago and Icon.

Plant-made pharmaceuticals are gaining increasing attention for their potential to aid in the production of therapeutic proteins to treat diseases such as cancer, HIV, heart disease, diabetes, Alzheimer’s disease, arthritis and many more.

Using plants as the vehicle for pharmaceutical production offers a variety of potential advantages, including fast and flexible supply to meet patient needs, lower capital investments than current methods and the ability to produce “difficult” proteins that are otherwise unavailable to the health professionals..

For more information or to register for the conference visit For more information on IALS and PlantPharma visit


Sarah Fuhrmann


# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website